TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8164029

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy
Number of subjects: 302

Group type: COMPARATOR
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo orally postchemotherapy
Number of subjects: 302
Study: 2845011

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (cyclophosphamide, Adriamycin, vincristine alternating with etoposide and cisplatin)
Number of subjects: 0
Study: 31994254

Group type: EXPERIMENTAL
Intervention: Juul (59 mg nicotine/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cigarettes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Other e-cigarette products
Number of subjects: 20
Study: 29710165

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention with wearable activity monitor and telephone coaching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (no onsite sessions, active exercise, or coaching)
Number of subjects: 200
Study: 26497643

Group type: EXPERIMENTAL
Intervention: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 4 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Mg-e HA at 4 months vs 12 months
Number of subjects: 20
Study: 24943283

Group type: EXPERIMENTAL
Intervention: Good practice treatment intervention (6 hours contact over 24 weeks, group-based)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Primary care control group
Number of subjects: 82
Study: 22457274

Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-infected children with ≥1 malaria episodes
Number of subjects: 0
Study: 20921347

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Literature Control (LC)
Number of subjects: 218
Study: 17726720

Group type: EXPERIMENTAL
Intervention: Citalopram (8-week trial)
Number of subjects: 84
Study: 15940441

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intracoronary brachytherapy
Number of subjects: 56
Study: 12578870

Group type: EXPERIMENTAL
Intervention: MCP‐1 levels >75th percentile (90th percentile in healthy volunteers)
Number of subjects: 2270
Study: 10530439

Group type: EXPERIMENTAL
Intervention: Microbial persistence evaluation using serology and PCR analysis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group of patients with end-stage heart disease of known cause
Number of subjects: 37
Study: 8688256

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl 4 micrograms ml‐1 (group F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.05% bupivacaine combined with fentanyl 2 micrograms ml‐1 (group BF)
Number of subjects: 60
Study: 8250364

Group type: EXPERIMENTAL
Intervention: Group B: 20 ml bolus of 0.25% bupivacaine followed by a continuous steady rate infusion (10 ml.h‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group C: Normal saline administered in the same way as Group B
Number of subjects: 20
Study: 3030861

Group type: EXPERIMENTAL
Intervention: DPTP vaccine (2 doses)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: DPT and IPV (2 doses)
Number of subjects: 320

Group type: COMPARATOR
Intervention: DPT and OPV (2 doses)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: DPTP vaccine (1 year follow-up)
Number of subjects: 320
Study: 31431338

Group type: EXPERIMENTAL
Intervention: Anterolateral ligament (ALL) tunnel aimed at 20° in the coronal plane and 0° in the axial plane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anterolateral ligament (ALL) tunnel aimed at 0° coronal and 40° axial angulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: ACL tunnel drilled by the AMP technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tunnel drilled at 0° in the axial plane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ALL tunnel orientation adjusted to avoid tunnel conflicts
Number of subjects: 32
Study: 29205049

Group type: EXPERIMENTAL
Intervention: Standard protocol (no ramping or pause)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ramping protocol alone
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ramping and pause protocols
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Pause protocol alone
Number of subjects: 320

Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 320
Study: 25367636

Group type: EXPERIMENTAL
Intervention: Stress management intervention combining individual cognitive behavioral therapy (CBT) with a brief workplace intervention (N=57)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (N=80)
Number of subjects: 137
Study: 22844781

Group type: EXPERIMENTAL
Intervention: 0.1% brimonidine tartrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 100
Study: 20151183

Group type: EXPERIMENTAL
Intervention: Syphilis and Men video intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study: 17413541

Group type: EXPERIMENTAL
Intervention: Training group (TG) performing glossopharyngeal pistoning (GP) for lung insufflation, 15-30 deep inspiratory efforts, three times per week for 6 weeks.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training group (TG) performing GP.
Number of subjects: 26
Study: 15309420

Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g glucose in 300 mL water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water alone (placebo control)
Number of subjects: 10
Study: 12540321

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antacids and H2 blockers
Number of subjects: 0
Study: 10433143

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 7659477

Group type: EXPERIMENTAL
Intervention: Lederle vaccine
Number of subjects: 403

Group type: COMPARATOR
Intervention: MPHBL vaccine
Number of subjects: 403
Study: 2679953

Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine cream (SSD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tulle gras (control dressing)
Number of subjects: 35
Study: 175434

Group type: EXPERIMENTAL
Intervention: Metacycline treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mycoplasma hominis
Number of subjects: 79
Study: 29766292

Group type: EXPERIMENTAL
Intervention: 10 g of extra virgin olive oil (EVOO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No EVOO
Number of subjects: 30
Study: 28618298

Group type: EXPERIMENTAL
Intervention: Online Behavioral Activation treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Higher baseline social functioning
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: No stressful life event during therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Completion of more online modules
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Concrete therapist focus
Number of subjects: 42
Study: 25051124

Group type: EXPERIMENTAL
Intervention: CAF-5 (5 mg.kg‐1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CAF-3 (3 mg.kg‐1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CAF-1 (1 mg.kg‐1)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study: 22772053

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (up to 190 mg once a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ivabradine (up to 7.5 mg twice daily)
Number of subjects: 20
Study: 21715537

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18037672

Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg kg(‐1) bolus and infusion of 5‐10 microg kg(‐1) min(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Ringer's lactate)
Number of subjects: 40
Study: 16431932

Group type: EXPERIMENTAL
Intervention: Blood withdrawal (450 ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (no blood withdrawal)
Number of subjects: 11
Study: 12858325

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 184
Study: 10881828

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg intravenously)
Number of subjects: 29
Study: 9196462

Group type: EXPERIMENTAL
Intervention: Bone-setting
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 114

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 114
Study: 8418243

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg/d
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 2868413

Group type: EXPERIMENTAL
Intervention: Intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days)
Number of subjects: 33
Study: 29535135

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) insulin delivery
Number of subjects: 16

Group type: COMPARATOR
Intervention: SAP insulin delivery
Number of subjects: 16
Study: 27721093

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 47
Study: 25037033

Group type: EXPERIMENTAL
Intervention: Heptavalent vaccine
Number of subjects: 480

Group type: COMPARATOR
Intervention: Hexavalent and monovalent MenC control vaccines
Number of subjects: 480
Study: 22311000

Group type: EXPERIMENTAL
Intervention: Peel-away sheath
Number of subjects: 201

Group type: COMPARATOR
Intervention: No peel-away sheath
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 201
Study: 20299307

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 4 days with a gap of 10 days, total 24 courses for 48 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vitamin C tablet (non-chewable, same dosage schedule as azithromycin)
Number of subjects: 50
Study: 18716298

Group type: EXPERIMENTAL
Intervention: Adalimumab (24 mg/m², max 40 mg, subcutaneously every other week for 16 weeks)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 171
Study: 16156905

Group type: EXPERIMENTAL
Intervention: Use of suction drains during surgery
Number of subjects: 8

Group type: COMPARATOR
Intervention: No use of suction drains during surgery
Number of subjects: 8
Study: 12407608

Group type: EXPERIMENTAL
Intervention: Prepuncture ultrasound guidance
Number of subjects: 240

Group type: COMPARATOR
Intervention: Landmark-guided puncture
Number of subjects: 240
Study: 10504107

Group type: EXPERIMENTAL
Intervention: Acute time-frame hospital-based video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 8756373

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 0.6 mg three times daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 1 mg twice daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 2 mg twice daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (all doses combined)
Number of subjects: 54
Study: 1743819

Group type: EXPERIMENTAL
Intervention: Nicotine (NI) chewing gum
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Silver acetate (SA) chewing gum
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (PL) chewing gum
Number of subjects: 496
Study: 7234694

Group type: EXPERIMENTAL
Intervention: Aspirin (4.0 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30721159

Group type: EXPERIMENTAL
Intervention: Body weight‐adapted CM protocol (0.4 g I/kg dosing factor, TIL adapted to weight)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Fixed CM dose (33 g I, 110 mL volume)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Body weight‐adapted CM protocol
Number of subjects: 199

Group type: COMPARATOR
Intervention: Fixed CM volume
Number of subjects: 199
Study: 30214029

Group type: EXPERIMENTAL
Intervention: Home visiting program (Nurse-Family Partnership)
Number of subjects: 512
Study: 24567912

Group type: EXPERIMENTAL
Intervention: Coherence analysis
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Graph theoretical network analyses
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Modularity analysis
Number of subjects: 308
Study: 22985437

Group type: COMPARATOR
Intervention: Normal-PI (NPI: 1.0 g/kg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-PI (HPI: 1.2 g/kg/day)
Number of subjects: 28
Study: 19007842

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 52
Study: 17719932

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (20 to 30 mg/kg/twice daily, adjusted to a peak serum concentration of 50 to 100 mug/mL)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 15513354

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control (subjects without dyspepsia)
Number of subjects: 142
Study: 11133596

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (50 microg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of intrathecal morphine and sufentanil
Number of subjects: 49

Group type: COMPARATOR
Intervention: IV morphine (patient-controlled analgesia)
Number of subjects: 49
Study: 9036884

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment at two atmospheres of pressure for 90 minutes twice a day for a minimum of 10 treatments
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group treated similarly but without HBO
Number of subjects: 125
Study: 7944639

Group type: EXPERIMENTAL
Intervention: 20 mg of hyaluronan (Hyalgan) in 2 ml of buffered saline, administered weekly for 5 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (inert vehicle)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Hyalgan (treatment group)
Number of subjects: 91
Study: 2979277

Group type: EXPERIMENTAL
Intervention: Ranitidine administration at 18.00 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine administration at 22.00 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine administration with food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine administration without food
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine administration at both times
Number of subjects: 12
Study: 31564620

Group type: EXPERIMENTAL
Intervention: External cooling and vibration devices
Number of subjects: 60

Group type: COMPARATOR
Intervention: Local mandibular anesthesia without any other procedure
Number of subjects: 60
Study: 30453344

Group type: EXPERIMENTAL
Intervention: Metoclopramide co-administration
Number of subjects: 9
Study: 27404010

Group type: COMPARATOR
Intervention: US $10 compensation
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Challenge with 'Are you tough enough?'
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Partner preference information
Number of subjects: 4000

Group type: COMPARATOR
Intervention: VMMC nurse hotline
Number of subjects: 4000
Study: 24043395

Group type: EXPERIMENTAL
Intervention: Moderate exercise (MOD; 300 kcal/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-dose exercise (HIGH; 600 kcal/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 61
Study: 22716224

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg (oral capsule)
Number of subjects: 15
Study: 20557937

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) by the same examiner
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) by different examiners
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Macular thickness program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fast macular thickness program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Threshold algorithm line failures
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Maximum retinal thickness (MRT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Age, lesion composition, examiner performing OCT examination, and sequence of examination
Number of subjects: 200
Study: 18698359

Group type: EXPERIMENTAL
Intervention: 20 microg of AMA1‐C1/Alhydrogel+564 microg CPG 7909 (n = 15)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 80 microg of AMA1‐C1/Alhydrogel+564 microg CPG 7909 (n = 30)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 80 microg of AMA1‐C1/Alhydrogel (n = 30)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AMA1‐C1/Alhydrogel+CPG 7909
Number of subjects: 75
Study: 17184595

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-treated with statin, Group II)
Number of subjects: 50
Study: 14529680

Group type: EXPERIMENTAL
Intervention: 3-h infusion of paclitaxel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6-h infusion of paclitaxel
Number of subjects: 12

Group type: COMPARATOR
Intervention: 24-h infusion of paclitaxel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-h vs 6-h infusion regimens
Number of subjects: 12
Study: 10068382

Group type: EXPERIMENTAL
Intervention: Olestra chips
Number of subjects: 3181

Group type: COMPARATOR
Intervention: Regular chips (control)
Number of subjects: 3181

Group type: COMPARATOR
Intervention: Olestra chips and Regular chips (control)
Number of subjects: 3181
Study: 8555662

Group type: EXPERIMENTAL
Intervention: MR imaging protocol at the University of Cincinnati Medical Center
Number of subjects: 18
Study: 1846934

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 6197766

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) at a constant dose of 8 ng kg‐1 min‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30550892

Group type: EXPERIMENTAL
Intervention: PUFA-rich meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5-day high PUFA diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: MUFA-rich meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5-day high MUFA diet
Number of subjects: 15
Study: 28952864

Group type: EXPERIMENTAL
Intervention: Otago Exercise Program with Motivational Interviewing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Otago Exercise Program without Motivational Interviewing
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Walking as part of the exercise program
Number of subjects: 114
Study: 26800392

Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg/bid) plus citalopram (40 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus citalopram (40 mg/day)
Number of subjects: 64
Study: 24304365

Group type: EXPERIMENTAL
Intervention: Open AVR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transapical TAVR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 52
Study: 22426408

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin weekly (60 mg/m2 paclitaxel and AUC 2.7 carboplatin)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Treatment adjustments due to toxicity
Number of subjects: 29
Study: 18781146

Group type: EXPERIMENTAL
Intervention: Genotypic stratification in smoking cessation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically stratified designs
Number of subjects: 0
Study: 17614270

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg QD
Number of subjects: 403

Group type: COMPARATOR
Intervention: Budesonide 800 microg QD
Number of subjects: 403
Study: 15655787

Group type: EXPERIMENTAL
Intervention: FP9 boosted by modified virus Ankara (MVA) encoding the malaria epitope‐thrombospondin‐related adhesion protein insert
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 used in heterologous prime‐boost immunization regimens with MVA encoding the circumsporozoite protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (unvaccinated)
Number of subjects: 0
Study: 12354426

Group type: EXPERIMENTAL
Intervention: Invasive strategy (angiography/revascularization between 4 and 48 hours)
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Invasive strategy among CK-negative but troponin-positive patients
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2220
Study: 9613535

Group type: EXPERIMENTAL
Intervention: 5 microg intrathecal sufentanil
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 10 microg intrathecal sufentanil
Number of subjects: 63
Study: 7655109

Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% cream applied once a day
Number of subjects: 449

Group type: COMPARATOR
Intervention: Bifonazole 1% cream applied once a day
Number of subjects: 449
Study: 2676121

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil (320 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control exercise stress tests
Number of subjects: 24